Regenerx Biopharmaceuticals lost $0.01 per diluted share in fiscal year 2022. That is unchanged from the prior fiscal year. Over the trailing 12 months, Q2 FY2022 through Q1 FY2023, the same line adds up to $0.00 per diluted share. The table below carries 13 fiscal years, from 2010 to 2022, and the quarters Regenerx Biopharmaceuticals has filed alongside them.
FY2022 annual
EPS (Diluted)-$0.01
YoY0.0%
Source SEC Filings (10-K/10-Q)Latest period Q1 FY2023, ended Mar 31, 2023ReportedCurrency USD
Annual figures, oldest first. Point at a bar to read its period.
RGRX EPS (Diluted) by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.
What was Regenerx Biopharmaceuticals's diluted earnings per share in fiscal year 2022?
Regenerx Biopharmaceuticals lost $0.01 per diluted share in fiscal year 2022.
How fast is Regenerx Biopharmaceuticals's diluted earnings per share growing?
Regenerx Biopharmaceuticals (RGRX) diluted earnings per share was essentially unchanged year over year, at -$0.01 in fiscal year 2022 against -$0.01 the year before.
What is Regenerx Biopharmaceuticals's diluted earnings per share over the last twelve months?
Regenerx Biopharmaceuticals (RGRX) reported $0.00 per diluted share over the trailing 12 months, Q2 FY2022 through Q1 FY2023, summed from the four most recent quarterly filings.
What was Regenerx Biopharmaceuticals's diluted earnings per share in the most recent quarter?
Regenerx Biopharmaceuticals (RGRX) reported $0.00 in diluted earnings per share in Q1 2023.
What does diluted earnings per share mean on a financial statement?
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Regenerx Biopharmaceuticals (RGRX) reported on that line in every period on record.
